Proxy Firms Recommend $9B Actavis-Warner Chilcott Deal

Law360, New York (August 29, 2013, 2:38 PM EDT) -- All three leading proxy advisers have endorsed the $9 billion merger of Actavis Inc. and Warner Chilcott PLC ahead of a shareholder vote next month, New Jersey-based Actavis said Thursday.

ISS Inc., Glass Lewis & Co. LLC and the smaller Egan-Jones Ratings Co. all say the deal, which will create a trans-Atlantic drug company with $10.5 billion in annual revenues, is in the best interests of Actavis shareholders. The endorsement — not particularly surprising given the lack of vocal opposition — comes ahead of a Sept....
To view the full article, register now.